Detalhe da pesquisa
1.
Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial.
Clin Exp Dermatol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38699939
2.
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
J Eur Acad Dermatol Venereol
; 38(5): 864-872, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38179809
3.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Br J Dermatol
; 189(5): 540-552, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488811
4.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
J Am Acad Dermatol
; 89(3): 478-485, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230366
5.
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
J Am Acad Dermatol
; 89(6): 1149-1158, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37553030
6.
Power analysis in a SMART design: sample size estimation for determining the best embedded dynamic treatment regime.
Biostatistics
; 21(3): 432-448, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380020
7.
Identifying a set that contains the best dynamic treatment regimes.
Biostatistics
; 17(1): 135-48, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26243172
8.
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
J Dermatolog Treat
; 33(7): 2991-2996, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839335
9.
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.
Dermatol Ther (Heidelb)
; 12(9): 2063-2075, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917057
10.
Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.
Arthritis Care Res (Hoboken)
; 74(2): 259-267, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32937016
11.
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Dermatol Ther (Heidelb)
; 12(2): 561-575, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050485
12.
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
JAMA Dermatol
; 157(9): 1047-1055, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347860
13.
Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome.
Stat Methods Med Res
; 29(7): 1891-1912, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571526
14.
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
JAMA Dermatol
; 156(6): 649-658, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32267471